nach oben

Endocrine

Erschienen in:

01.08.2013 | Review

Osteoporosis in men: recent progress

verfasst von: Robert A. Adler

Erschienen in: Endocrine | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

As osteoporosis in men has been recognized as an important clinical problem, new information is being accumulated on its scope, pathophysiology, evaluation, and treatment. Fracture risk calculators, such as FRAX, identify a large proportion of the older male population to be at heightened risk for fracture. The classification of osteoporosis into primary and secondary forms, while still useful, is affected by the fact that many men have multiple contributing factors to their fracture risk. The role of sex steroids is being better defined as other risk factors for fracture are delineated. As longevity continues to increase in men and until osteoporotic fracture is truly recognized as a potentially fatal disorder, many men will be undiagnosed and untreated. Two recent studies provide more evidence that treatments which decrease fracture risk in women do the same in men. With the publication of guidelines and increasing strength of evidence for treatment efficacy, it is hoped that more men will be evaluated and treated for this often neglected disorder.

R. Burge, B. Dawson-Hughes, D.H. Solomon, J.B. Wong, A. King, A.N. Toteston, Incidence and economic burden of osteoporosis-related fracture and subsequent fracture in men and women. JAMA 22, 365–475 (2007)

S. Khosla, L.J. Melton III, E.J. Atkinson, W.M. O’Falon, Relationship of serum sex steroids to longitudinal changes in bone density in young versus elderly men. J. Clin. Endocrinol. Metab. 86, 3555–3561 (2001)PubMedCrossRef

T.P. van Staa, E.M. Dennison, H.G. Leufkens, C. Cooper, Epidemiology of fractures in England and Wales. Bone 29, 517–522 (2001)PubMedCrossRef

R.B. Hopkins, E. Pullenayegum, R. Goeree, J.D. Adachi, A. Papaioannou, W.E. Leslie, J.E. Tarride, L. Thabane, Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos. Int. 23, 921–927 (2012)PubMedCrossRef

A.C. Feldstein, G. Nichols, E. Orwoll, P.J. Elmer, D.H. Smith, M. Herson, M. Aickin, The near absence of osteoporosis treatment in older men with fractures. Osteoporos. Int. 16, 953–962 (2005)PubMedCrossRef

J.R. Center, D. Bliuc, T.V. Nguyen, J.A. Eisman, Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 24, 387–394 (2007)CrossRef

J.E. Block, H. Stubbs, Hip fracture-associated mortality reconsidered. Calcif. Tissue Int. 61, 84 (1997)PubMedCrossRef

T.P. van Staa, H.G. Leufkens, L. Abenhaim, B. Zhang, C. Cooper, Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxf.) 39, 1383–1389 (2000)CrossRef

R.A. Adler, M.C. Hochberg, Glucocorticoid-induced osteoporosis in men. J. Endocrinol. Investig. 34, 481–484 (2011)

10.

G.L. Lu-Yao, P.C. Albertsen, D.F. Moore, W. Shih, Y. Lin, R.S. DiPaola, S.L. Yao, Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300, 173–181 (2008)PubMedCrossRef

11.

V.B. Shahinian, Y.F. Kuo, J.L. Freeman, J.S. Goodwin, Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154–164 (2005)PubMedCrossRef

12.

B.L. Riggs, L.J. Melton III, Involutional osteoporosis. N. Engl. J. Med. 314, 1676–1686 (1986)PubMedCrossRef

13.

R.A. Adler, Osteoporosis in men: insights for the clinician. Ther Adv Musculoskelet Dis 3, 191–200 (2011)PubMedCrossRef

14.

J.A. Kanis, H. Johansson, A. Oden, B. Dawson-Hughes, L.J. Melton III, E.V. McCloskey, The effects of a FRAX revision for the USA. Osteoporos. Int. 21, 35–40 (2010)PubMedCrossRef

15.

N.D. Nguyen, S.A. Frost, J.R. Center, J.A. Eisman, T.V. Nguyen, Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos. Int. 18, 1109–1117 (2008)CrossRef

16.

C.S. Ryan, V.I. Petkov, R.A. Adler, Osteoporosis in men: the value of laboratory testing. Osteoporos. Int. 22, 1845–1853 (2011)PubMedCrossRef

17.

E. Romagnoli, R. Del Fiacco, S. Russo, S. Piemonte, F. Fidanza, F. Colapietro, D. Diacinti, C. Cipriani, S. Minisola, Secondary osteoporosis in men and women: clinical challenge of an unresolved issue. J. Rheumatol. 38, 1671–1679 (2011)PubMedCrossRef

18.

L.E. Ryan, S.W. Ing, Idiopathic hypercalciuria and bone health. Curr. Osteoporos. Rep. 10, 286–295 (2012)PubMedCrossRef

19.

P. Vestergaard, L. Rejnmark, L. Mosekilde, Fracture risk associated with the use of morphine and opiates. J. Intern. Med. 260, 76–87 (2006)PubMedCrossRef

20.

S.M. Harman, E.J. Metter, J.D. Tobin, J. Pearson, M.R. Blackman, Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. 86, 724–731 (2001)PubMedCrossRef

21.

J.M. Kaufman, A. Vermeulen, The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 26, 833–876 (2005)PubMedCrossRef

22.

G. Sartorius, S. Spasevska, A. Idan, L. Turner, E. Forbes, A. Zamojska, C.A. Allan, L.P. Ly, A.J. Conway, R.I. McLachlan, D.J. Handelsman, Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin. Endocrinol. 77, 755–763 (2012)CrossRef

23.

P. Dandona, S. Dhindsa, Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J. Clin. Endocrinol. Metab. 96, 2643–2651 (2011)PubMedCrossRef

24.

K.M. Wiren, A. Chapman Evans, X.W. Zhang, Osteoblast differentiation influences androgen and estrogen receptor-alpha and -beta expression. J. Endocrinol. 175, 683–694 (2002)PubMedCrossRef

25.

H. Lee, J.S. Finkelstein, M. Miller, S.J. Comeaux, R.I. Cohen, B.Z. Leder, Effects of selective testosterone and estradiol withdrawal on skeletal sensitivity to parathyroid hormone in men. J. Clin. Endocrinol. Metab. 91, 1069–1075 (2006)PubMedCrossRef

26.

D. Merlotti, L. Gennari, K. Stolakis, R. Nuti, Aromatase activity and bone loss in men. J. Osteoporos. 2011, 230671 (2011). doi:10.4061/2011/230671 PubMed

27.

C.M. Nielson, L.M. Marshall, A.L. Adams, E.S. LeBlanc, P.M. Cawthon, K. Ensrud, E. Barrett-Connor, E.S. Orwoll, Osteoporotic Fractures in Men Study Research Group. BMI and fracture risk in older men: the osteoporotic fractures in men study (MrOS). J. Bone Miner. Res. 26, 496–502 (2011)PubMedCrossRef

28.

L.A. Fitzpatrick, Secondary causes of osteoporosis. Mayo Clin. Proc. 77, 453–468 (2002)PubMed

29.

R.A. Adler, Laboratory testing for secondary osteoporosis evaluation. Clin. Biochem. 45, 894–900 (2012)PubMedCrossRef

30.

G. Mazziotti, T. Porcelli, M. Mormando, E. De Menis, A. Bianchi, C. Mejia, T. Mancini, L. De Marinis, A. Giiustina, Vertebral fractures in males with prolactinoma. Endocrine 39, 288–293 (2011)PubMedCrossRef

31.

C. Torti, G. Mazziotti, P.A. Soldini, E. Foca, R. Maroldi, D. Gotti, G. Carosi, A. Giustina, High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41, 512–517 (2012)PubMedCrossRef

32.

T.T. Dam, S. Harrison, H.A. Fink, J. Ramsdell, E. Barrett-Connor, Osteoporotic Fractures in Men (MrOS) Research Group, Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos. Int. 21, 1341–1349 (2010)PubMedCrossRef

33.

G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877–884 (2010)PubMedCrossRef

34.

C.E. Lewis, S.K. Ewing, B.C. Taylor, J.M. Shikany, H.A. Fink, K.E. Ensrud, E. Barrett-Connor, S.R. Cummings, E.S. Orwoll, Osteoporotic Fractures in Men (MrOs) Study Research Group, Predictors of non-spine fracture in elderly men: the MrOS Study. J. Bone Miner. Res. 22, 211–219 (2007)PubMedCrossRef

35.

J.A. Cauley, G. El Hajj Fuleihan, A. Arabi, S. Fujiwara, S. Ragi-Eis, A. Calderon, S.B. Chionh, Z. Chen, J.R. Curtis, M.E. Danielson, D.A. Hanley, H. Kroger, A.W. Kung, O. Lesnyak, J. Nieves, W. Pluskiewicz, R. El Rassi, S. Silverman, A.M. Schott, R. Rizzoli, M. Luckey, FRAX Position Conference Members, Official positions for FRAX clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis on FRAX. J. Clin. Densitom. 14, 240–262 (2011)PubMedCrossRef

36.

J.P. Bilezikian, S.J. Silverberg, Normocalcemic primary hyperparathyroidism. Arq. Bras. Endocrinol. Metab. 54, 106–109 (2010)CrossRef

37.

N. Binkley, R.A. Adler, Dual-energy X-ray absorptiometry (DXA) in men, in Osteoporosis in Men, 2nd edn., ed. by E.S. Orwoll, J.P. Bilezikian, D. Vanderschueren (Academic Press, New York, 2010), pp. 525–540CrossRef

38.

T. Isaksen, C.S. Nielsen, S.E. Christensen, P.H. Nissen, L. Heickendorff, L. Mosekilde, Forearm bone mineral density in familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a comparative study. Calcif. Tissue Int. 89, 285–294 (2011)PubMedCrossRef

39.

D.K. Dhanwal, N. Kochupillai, N. Gupta, C. Cooper, E.M. Dennison, Hypovitaminosis D and bone mineral metabolism and bone density in hyperthyroidism. J. Clin. Densitom. 13, 462–466 (2010)PubMedCrossRef

40.

D. Mittan, S. Lee, E. Miller, R.C. Perez, J.W. Basler, J.M. Bruder, Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J. Clin. Endocrinol. Metab. 87, 3656–3661 (2002)PubMedCrossRef

41.

J.A. Kanis, L.J. Melton III, C. Christiansen, C.C. Johnston, N. Khaltaev, The diagnosis of osteoporosis. J. Bone Miner. Res. 9, 1137–1141 (1994)PubMedCrossRef

42.

J.A. Kanis, G. Bianchi, J.P. Bilezikian, J.M. Kaufman, S. Khosla, E. Orwoll, E. Seeman, Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos. Int. 22, 2789–2798 (2011)PubMedCrossRef

43.

P.L. Selby, P.L. Davies, J.E. Adams, Do men and women fracture bones at similar bone densities? Osteoporos. Int. 11, 153–157 (2000)PubMedCrossRef

44.

R.A. Adler, Osteoporosis in men: what has changed? Curr. Osteoporos. Rep. 9, 31–35 (2011)PubMedCrossRef

45.

M.G. Donaldson, P.M. Cawthon, L.Y. Lui, J.T. Schousboe, K.E. Ensrud, B.C. Taylor, J.A. Cauley, T.A. Hillier, T.T. Dam, J.R. Curtis, D.M. Black, D.C. Bauer, E.S. Orwoll, S.R. Cummings, Osteoporotic Fractures in Men (MrOS) Study Group, Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation Guidelines. J. Bone Miner. Res. 25, 1506–1511 (2010)PubMedCrossRef

46.

G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatment for osteoporosis. Endocrine 41, 58–69 (2012)PubMedCrossRef

47.

E.S. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Graham, S. Adami, K. Weber, R. Lorenc, P. Pietschmann, K. Vandormael, A. Lombardi, Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 343, 604–610 (2000)PubMedCrossRef

48.

L.H. Klotz, I.Y. McNeill, M. Kebabdjian, L. Zhang, J. Chin, Canadian Urology Research Consortium, A phase 3, double-blind, randomized, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and osteoporosis research with alendronate and leuprolide (CORAL) study. Eur. Urol. doi:10.1016/j.eururu.2012.09.007

49.

S. Boonen, E.S. Orwoll, D. Wenderoth, K.J. Stoner, R. Eusebio, P.D. Delmas, Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J. Bone Miner. Res. 24, 719–725 (2009)PubMedCrossRef

50.

P. Taxel, R. Dowsett, L. Richter, P. Fall, A. Klepinger, P. Albertsen, Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int. 106, 1473–1476 (2010)PubMedCrossRef

51.

E.S. Orwoll, N.C. Binkley, E.M. Lewiecki, U. Gruntmanis, M.A. Fries, G. Dasic, Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46, 970–976 (2010)PubMedCrossRef

52.

E.S. Orwoll, P.D. Miller, J.D. Adachi, J. Brown, R.A. Adler, D. Kendler, C. Bucci-Rechtweg, A. Readie, P. Messenbrink, R.S. Weinstein, Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J. Bone Miner. Res. 25, 2239–2250 (2010)PubMedCrossRef

53.

S. Boonen, J.Y. Reginster, J.M. Kaufman, K. Lippuner, J. Zanchetta, B. Langdahl, R. Rizzoli, S. Lipschitz, H.P. Dimai, R. Witvrouw, E. Eriksen, K. Brixen, L. Russo, F. Claessens, P. Papanastasiou, O. Antunez, G. Su, C. Bucci-Rechtweg, J. Hruska, E. Incera, D. Vanderschueren, E. Orwoll, Fracture risk and zoledronic acid therapy in men with osteoporosis. N. Engl. J. Med. 367, 1714–1723 (2012)PubMedCrossRef

54.

K. Sinningen, E. Tsourdi, M. Rauner, T.D. Rachner, C. Hamann, L.C. Hofbauer, Skeletal and extraskeletal actions of denosumab. Endocrine 42, 52–62 (2012)PubMedCrossRef

55.

E. Orwoll, C.S. Teglbjaerg, B.L. Langdahl, R. Chapurlat, E. Czerwinski, D.L. Kendler, J.Y. Reginster, A. Kivitz, E.M. Lewiecki, P.D. Miller, M.A. Bolognese, M.R. McClung, H.G. Bone, P. Ljimggrem, B. Abrahamsne, U. Gruntmanis, Y.C. Yang, R.B. Wagman, S. Siddhanti, A. Grauer, J.W. Hall, S. Boonen, A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J. Clin. Endocrinol. Metab. 97, 3161–3169 (2012)PubMedCrossRef

56.

M.R. Smith, B. Egerdie, N.H. Toriz, R. Feldman, T.L. Tammela, F. Saad, J. Heracek, M. Szwedowski, C. Ke, A. Kupic, B.Z. Leder, C. Goessl, Denosumab HALT Prostate Cancer Study Group, Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745–755 (2009)PubMedCrossRef

57.

N.E. Cusano, A.G. Costa, B.C. Silva, J.P. Bilezikian, Therapy of osteoporosis in men with teriparatide. J. Osteoporos. 2011, 463675 (2011). doi:10.4061/2011/463675

58.

J.M. Kaufman, E. Orwoll, S. Goemaere, J. San Martin, A. Hossain, G.P. Dalsky, R. Linsday, B.H. Mitlak, Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos. Int. 16, 510–516 (2005)PubMedCrossRef

59.

J.D. Ringe, A. Dorst, P. Farahmand, Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittelforschung 60, 267–272 (2010)PubMed

60.

H.M. Behre, S. Kliesch, E. Leifke, T.M. Link, E. Nieschlag, Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 82, 2386–2390 (1997)

61.

J.K. Amory, N.B. Watts, K.A. Easley, P.R. Sutton, B.D. Anawalt, A.M. Matsumoto, W.J. Bremer, J.L. Tenover, Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab. 89, 503–510 (2004)PubMedCrossRef

62.

P.J. Snyder, H. Peachey, P. Hannoush, J.A. Berlin, L. Loh, J.H. Holmes, A. Dlewati, J. Staley, J. Santanna, S.C. Kapoor, M.F. Attie, J.G. Haddad Jr., B.L. Strom, Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. 84, 1966–1972 (1999)PubMedCrossRef

63.

N.B. Watts, R.A. Adler, J.P. Bilezikian, M.T. Drake, R. Eastell, E.S. Orwoll, J.S. Finkelstein, Osteoporosis in men: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 97, 1802–1822 (2012)PubMedCrossRef

64.

J. Compston, Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos. Int. 22, 2951–2961 (2011)PubMedCrossRef

65.

S.V. Reddy, S.K. Gupta, Atypical femoral shaft fractures in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence? Singap. Med. J. 53, e52–e54 (2012)

66.

N.B. Watts, D.L. Diab, Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab. 95, 1555–1565 (2010)PubMedCrossRef

Titel: Osteoporosis in men: recent progress
verfasst von: Robert A. Adler
Publikationsdatum: 01.08.2013
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2013
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-013-9880-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Wilson disease, genotype and infertility: is there a correlation?

Everolimus therapy for progressive adrenocortical cancer

Is there a role for combination therapy for osteoporosis?

Autoimmune thyroid disease: a novel risk factor for atherosclerosis?

The relationship between physical activity, restless legs syndrome, and health-related quality of life in type 2 diabetes